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Abstract:
We report a primary diffuse large B-cell lym-
phoma of uterine corpus in a 70-years-old
woman who presented with symptoms of in-
creased urinary frequency and sense of bloat-
ing. Magnetic Resonance Imaging (MRI) find-
ings were suggestive of a degenerating intra-
mural fibroid. Histological examination of tis-
sue samples obtained during hysteroscopy
showed diffuse infiltration of fibrous stroma
by atypical enlarged mononuclear cells. Immu-
nohistochemical studies were consistent with
the diagnosis of diffuse large B-cell lymphoma.
Further imaging studies showed no evidence of
lymphoma outside the uterus. To our knowledge,
this represents the first well-documented case
of primary uterine lymphoma presenting as a
leiomyoma on imaging studies.
Key Words: Non-Hodgkin lymphoma, uter-
ine corpus, DLBCL, fibroids.
Introduction:
Diffuse large B-cell lymphoma (DLBCL) is the
most common type of adult non-Hodgkin lym-
phoma (NHL). In the western world it consti-
tutes close to one third of all NHL and the esti-
mates are even higher in the developing nations
[1]. DLBCL most commonly occurs in the eld-
erly population with slight male predominance
[1]. DLBCL that arises de novo is referred to
as primary; whereas in cases of progression or
transformation from other small B-cell lym-
phomas, it is referred to as secondary DLBCL
and like other NHL it can initially involve ei-
ther nodal or extra-nodal sites. The most com-
mon primary extranodal location is the gas-
trointestinal tract; however other relatively fre-
quent sites include bone, testis, salivary gland,
thyroid, liver, kidney and adrenal gland [1]. Al-
though disseminated involvement of the female
genital tract by NHL is not that uncommon, pri-
mary NHL are very rare in that location and
usually involve the ovary or uterine cervix [2].
We describe a case of DLBCL of the uterine
corpus that mimicked a degenerating lei-
omyoma on magnetic resonance imaging (MRI)
and highlight both its unusual location and atypi-
cal clinical presentation.
Case Report:
A 70-years-old Caucasian woman (gravida 3,
para3) presented with urinary frequency and a
sense of bloating. Physical examination & review
of systems were unremarkable, except as men-
tioned above. Past medical history was non-
contributory. The patient had a 25 pack-year of
smoking history. She underwent pelvic ultra-
sound that revealed a 3 x 3 x 2.9 cm hypoechoic
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solid lesion within the posterior wall of the
uterus (Fig. 1A).
A subsequent MRI revealed a circumscribed
mass in the left uterine fundus with image fea-
tures most consistent with a degenerating in-
tramural leiomyoma (Fig. 1B). The patient un-
derwent hysteroscopy that revealed what ap-
peared at that time a transmural fibroid extend-
ing prominently into the endometrial cavity. A
significant portion of the endometrial protrud-
ing mass was removed and submitted for histo-
logic evaluation that showed a high-grade dif-
fuse large B-cell lymphoma. PET-CT demon-
strated an fludeoxyglucose (FDG)-avid lesion
confined to the uterus without evidence of other
FDG-avid disease in the head, neck, chest,
abdomen or pelvis. Following the histologic
diagnosis, the patient was started on R-CHOP
(Rituximab, Cyclophosphamide,
Hydroxydaunorubicin, Oncovin and Predniso-
lone) chemotherapy regimen. PET imaging fol-
lowing three cycles of R-CHOP, showed the
previously-noted uptake within the uterus had
completely resolved and the uterine fundus had
decreased in size. There was no other FDG-avid
disease anywhere in the body. CT scan prior to
the patients sixth and last cycle of chemo-
therapy showed no evidence of adenopathy or
any other sign of lymphoma. Follow-up CT scan
three years later showed no evidence of recur-
rence.
Pathologic Findings:
The tissue samples obtained by endometrial
curettage had an unremarkable macroscopic
appearance consisting of multiple white and pink
soft tissue fragments measuring 3.5 x 3.5 x 1
cm in aggregate. Microscopic examination of
the sections revealed fragments of fibrous tis-
sue with a diffuse lymphoid infiltrate, composed
predominantly of intermediate to large sized
cells with round to irregular nuclear contours,
prominent nucleoli, vesicular chromatin, and a
moderate amount of cytoplasm. Scattered
apoptotic figures were noted. No areas of tu-
Fig1. A, Axial ultrasound image of the uterine fundus shows
a well-circumscribed, homogeneously hypoechoic mass with
increased through-transmission. Doppler interrogation
shows internal vascularity (orange areas).
B, Axial T2-weighted MRI through the uterine fundus shows
homogeneous well-circumscribed mass with myometrial
and submucosal components, and resultant distortion of
the endometrium.Ó Journal of Krishna Institute of Medical Sciences University
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mour necrosis were identified within the speci-
men. Small lymphocytes were present in the
 B, High-power view of the lesion demonstrating large lym-
phoid cells with irregular nuclei, prominent nucleoli and
moderate amount of cytoplasm admixed with small lympho-
cytes (hematoxylin-eosin, original magnification x600).
background (Fig. 2A & B). The endometrium
showed atrophic changes and otherwise was
unremarkable.
Fig. 2. A, Microscopic view of a tissue sample with diffuse
lymphoid infiltration (hematoxylin-eosin, original magnifi-
cation x200).
Fig. 3. A, CD20 immunoperoxidase stain (original magnifi-
                 cation x600).
Fig. 3. C, BCL2 immunoperoxidase stain (original magnifi-
                 cation x600).
Fig. 3. B, CD10 immunoperoxidase stain (original magnifi-
                 cation x600).
Fig. 3. D, MIB1 immunoperoxidase stain (original magnifi-
                 cation x600)Ó Journal of Krishna Institute of Medical Sciences University
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Immunohistochemically, the tumour cells
showed strong positivity for leukocyte common
antigen (LCA). CD20 diffusely highlighted
large B-cells (Fig. 3A). CD10, BCL2 and BCL6
were also diffusely co-expressed within the
large B-cells (Fig. 3B & C).
CD3 and CD5 stained scattered T-cells.  CD5
co-expression within the B-cells was not seen.
DRC (dendritic reticulum cells), BCL1 and
nTdT were mostly negative. MIB1 highlighted
a large fraction (70-80%) of proliferating cells
(Fig. 3D). The combination of morphological
and immunohistochemical findings were con-
sistent with diffuse large B-cell lymphoma.
Given the absence of any other nodal or extrau-
terine lymphoid proliferation, the diagnosis was
primary uterine lymphoma.  The patient was
treated with R-CHOP and followed up regularly.
After 36 months of diagnosis she had no evi-
dence of nodal or extranodal forms of lym-
phoma.
Discussion:
Primary NHL of the female reproductive tract
is a rare entity, accounting for up to 2% of ex-
tra-nodal malignant lymphomas [3]. According
to Frey et al, reviews of individual institutional
databases estimate that primary lymphomas of
the uterus and cervix approach a little over half
a percent of all extra-nodal NHL, with uterine
corpus involvement being the least common site
of all [4]. An analysis of twenty-six uterine NHL
cases, collected at M.D. Anderson Cancer Cen-
ter over an eighteen year period, has concluded
that the prevailing majority are of B-cell lin-
eage with DLBCL being the most common his-
tologic type [2]. In addition to DLBCL, there
are less frequent reports of the uterine follicu-
lar lymphoma, marginal zone B-cell lymphoma,
small lymphocytic lymphoma and Burkitts
lymphoma [2, 4]. Primary uterine NHLs with
B-cell phenotype are much more common than
T-cell lymphomas and there are even fewer
cases of natural killer-cell lymphomas [2, 5].
At the same time, secondary uterine involve-
ment by any of these NHL occurs much more
frequently. In fact, some reported cases of uter-
ine lymphoma (including T-cell, small lympho-
cytic and Burkitts lymphomas) lack clear evi-
dence of being primary and likely represent lym-
phomas that originated in other sites [2, 4].
While primary and secondary involvement is
not defined in uterine lymphomas, just as in
other organ sites (e.g., primary bone lym-
phoma) unequivocal absence of nodal or other
extranodal involvement at the time of presen-
tation or (arbitrarily) 6 months around diagno-
sis may be sufficient evidence for a diagnosis
of primary uterine lymphoma.
Primary uterine NHL most commonly occur in
women in their mid-50s  and cause a spectrum
of clinical manifestations ranging from severe
uterine bleeding requiring transfusions, arterial
embolization and even emergent hysterectomy
to being asymptomatic and diagnosed inciden-
tally [4, 6]. Menorrhagia, metrorrhagia, irregu-
lar menses, post-coital bleeding, post-meno-
pausal bleeding and other forms of dysfunc-
tional uterine bleeding comprise up to two-
thirds of all clinical presentations, followed by
pelvic pain frequently associated with a palpable
mass [2, 4]. Extrinsic compression of the blad-
der, as well as other urinary structures, by an
enlarging mass within genital tract organs (cer-
vix, vagina and vulva) produces in some patients
urinary symptoms such as increased frequency
and urgency [7]. There are also reports of pa-Ó Journal of Krishna Institute of Medical Sciences University
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tients presenting with cervical and endometrial
polyps [2, 8, 9]. Asymptomatic patients have
been diagnosed by routine gynecologic exams
and PAP smears. In some cases, the diagnosis
of uterine lymphoma could be established in-
cidentally in total abdominal hysterectomy
specimens obtained for other conditions or
during post-mortem examinations [2].
We describe a case of DLBCL of the uterine
corpus with an unique constellation of clinical
features. To our knowledge, all previously re-
ported cases of primary NHL localized to cor-
pus of the uterus have manifested exclusively
with abnormal uterine bleeding. Vang et al in
their analysis of uterine NHL has identified only
one case of a 69 years-old female who presented
with increasing urinary frequency and rectal
urgency, but in this patient, the lymphoma likely
has originated in an extrauterine site [2]. Ours
is the first case of primary lymphoma of the
uterine corpus causing urinary frequency and
bloating. 
Prior to histologic examination, the diagnosis
of leiomyoma was favoured based on radiologi-
cal and clinical findings. To date, few case re-
ports describe imaging findings of primary
uterine lymphoma and there is no constellation
of radiologic features that are diagnostic of
uterine lymphoma. Previous descriptions re-
veal variable appearances, including involve-
ment of the cervix, large infiltrative mass-like
tumour, diffuse enlargement of the uterus, mul-
tilobular or septated morphology, invasion of
adjacent pelvic structures (such as vagina, blad-
der or parametrium) and pelvic lymphadenopa-
thy [10]. All report relatively homogeneous tu-
mour signal on MRI, described as intermedi-
ate-to-low T1 and intermediate-to-increased
T2-weighted signal. While some case reports
suggest preservation of the endometrium or
junctional zone as a specific finding of uterine
lymphoma, other cases have shown at least par-
tial preservation of the endometrium or nor-
mal uterine or cervical zonal anatomy, and yet
other cases have shown no normal en-
dometrium or junctional zone [10]. In our case,
both transvaginal ultrasound and MR imaging
of the uterus has shown a solitary well-circum-
scribed, homogeneous, solid, vascularized mass
with a single septation within the posterior fun-
dus. The mass has been present in the myo-
metrium and submucosa, causing distortion of
the endometrial cavity, but with a largely pre-
served junctional zone. As opposed to most
cases reported in the literature, there has been
no evidence of invasion into adjacent pelvic
structures, including the cervix, vagina,
parametrium, ovaries, bladder and urethra.
There has been also no lymphadenopathy dem-
onstrated in the pelvis. On ultrasound, the mass
has been hypoechoic with increased through-
transmission and posterior wall enhancement,
findings which mimic cysts, but given internal
vascularity represents a mass or a solid lesion.
This can be seen in homogeneous, cellular
tumours such as lymphoma or certain me-
tastases. Of note, this mass was not visualized
on pelvic ultrasound performed little over a
year prior, thus rendering benign etiology less
likely in this postmenopausal patient. However,
on MRI, the mass has exhibited homogeneous
mildly increased T2-weighted signal and mildly
decreased T1-weighted signal compared to the
adjacent myometrium, as well as homogeneous
mild enhancement after administration of ga-
dolinium-containing IV contrast material, fea-
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tures which may be seen in either a degenerat-
ing leiomyoma or lymphoma among other neo-
plasms. The combination of MRI and morpho-
logic findings (both during hysteroscopy and
gross pathology exam) of this well-circum-
scribed myometrial-based lesion has placed
fibroid high in the differential. In fact, both
gynecologists and pathologists initially have
approached it as a trivial case of leiomyoma.
The histologic differential diagnosis for NHL
involving the uterus includes other hematologic
malignancies (i.e. Burkitt lymphoma), endome-
trial stromal sarcoma (ESS) and Ewing sarcoma
(ES) / primitive neuroectodermal tumour
(PNET). Poorly differentiated or undifferenti-
ated carcinomas and melanoma should also be
in the differential diagnosis. Prior to consid-
ering any neoplastic process, a florid benign
reactive lymphoid proliferation should be ex-
cluded. In contrast to monomorphic appearing
lymphomas, reactive lesions typically have
non-infiltrating features and are composed of
mixed populations of lymphocytes, plasma
cells, neutrophils and tingible body macroph-
ages.
Given high-grade features, relatively high pro-
liferation by MIB1 and focal presence of
apoptotic bodies seen the specimen, Burkitt
lymphoma, as well as a large B-cell lymphoma,
unclassifiable, with features intermediate be-
tween DLBCL and Burkitt lymphoma (Burkitt-
like lymphoma) are considered in the differ-
ential diagnosis. The classic Burkitt lymphoma
cytologically reveals rounded cells with mod-
erate amounts of mid-night velveteen blue
cytoplasm with punched out vacuoles; nuclear
features resembling a L3 (lymphoblastic) mor-
phology, including 1-3 somewhat peripherally
placed nucleoli being frequently present. In ad-
dition, most, if not all, cases of classic Burkitt
lymphoma are BCL2 negative. In our case, tu-
mour cells are BCL2 positive with no cytoplas-
mic vacuoles or nuclear features that overlaps
with Burkitt lymphoma. In addition, the clas-
sic starry sky appearance characteristic of
Burkitt lymphoma seen under low power due
to scattered tingible body-laden macrophages
is not appreciated in the specimen. Further-
more, the patient has been treated with R-
CHOP chemotherapy (standard regimen for
large B-cell lymphoma) and she has remained
in complete remission with no evidence of
nodal or extranodal disease for more than 36
months. Burkitt or Burkitt-like lymphoma will
not have responded to standard R-CHOP alone.
Among other hematologic malignancies that
can mimic NHL are poorly differentiated ex-
tramedullary myeloid cell tumour and Langer-
hans cell histiocytosis [2]. Both neoplasms lack
lymphoid markers.
Distinguishing between an endometrial stromal
sarcoma in particular with sex cord elements
and NHL may pose an initial diagnostic chal-
lenge on H&E sections. However, absence of
sarcomatoid cell spindling and prominent ar-
borizing vasculature, as well as presence of
lymphoid staining profile, provides clues to the
diagnosis of lymphoma [2]. ES/PNET can have
a lymphoma-like growth pattern with enlarged
tumor cells, prominent nucleoli and irregular
contours; however lack of lymphoid markers
(except CD99) distinguishes it from NHL [2].
Due to rarity of primary NHL in the female
genital tract, to date, no randomized clinical
trials have been performed to outline the best
approach to treatment. A variety of therapeutic
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modalities and different combinations of che-
motherapy, immunotherapy, surgery and radio-
therapy have been reported with a range of out-
comes and survival rates. One group has re-
ported successful pregnancy occurring after
chemo-radiotherapy in a 29-years-old female
with DLBCL of the uterine cervix [11]. The
most recent data, however, suggests that over-
all NHL involving rare extranodal sites includ-
ing uterus have a poor prognosis with the me-
dian overall survival of slightly over 16 months
[12]. The 5 year overall survival rate, as deter-
mined by a recent analysis of 28 cases of pri-
mary malignant lymphoma involving female
genital tract, is 39.3% [13]. A study of surgical
and non-surgical treatment modalities has con-
cluded that chemotherapy may play a more im-
portant role than surgical intervention in treat-
ing primary genital lymphomas [14]. In regards
to rituximab use, there are conflicting reports.
Cvetkovic et al have reported that rituximab in
combination with chemotherapy is a valuable
option for patients with aggressive B-cell NHL
[15]. Yun et al, on the other hand have indicated
that a combination of rituximab and chemo-
therapy (CHOP) failed to provide an additive
survival benefit over the same chemotherapy
alone [12].
In summary, we have reported a case of pri-
mary DLBCL involving exclusively uterine
corpus and presenting with urinary symptoms
and sense of bloating. Imaging findings have
included a relatively wide differential diagno-
sis including lymphoma and degenerating lei-
omyoma depending on the study. Although lym-
phoma of the female genital tract has an ex-
ceedingly low incidence, it should be kept in
mind in patients presenting with persistent uri-
nary symptoms and sense of bloating. When-
ever features of leiomyoma, especially degen-
erating, are seen on MR imaging, uterine lym-
phoma should also be considered in the differ-
ential diagnosis.
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